The FDA faces significant institutional challenges extending far beyond recent confirmation hearing discussions on mifepristone and vaccines. Heidi Overton's hearing highlighted regulatory concerns, but experts argue the agency's struggles reflect deeper systemic issues including decision-making processes, scientific credibility, and stakeholder trust. These fundamental problems require comprehensive reform to restore public confidence and ensure effective pharmaceutical oversight and policy implementation across all agency functions.

Summary auto-generated by AI from the original publisher's content. Editorial standards.